Literature DB >> 15994391

The protease inhibitor PI*S allele and COPD: a meta-analysis.

M Dahl1, C P Hersh, N P Ly, C S Berkey, E K Silverman, B G Nordestgaard.   

Abstract

In many countries, the protease inhibitor (SERPINA1) PI*S allele is more common than PI*Z, the allele responsible for most cases of chronic obstructive pulmonary disease (COPD) due to severe alpha 1-antitrypsin deficiency. However, the risk of COPD due to the PI*S allele is not clear. The current authors located studies that addressed the risk of COPD or measured lung function in individuals with the PI SZ, PI MS and PI SS genotypes. A separate meta-analysis for each genotype was performed. Aggregating data from six studies, the odds ratio (OR) for COPD in PI SZ compound heterozygotes compared with PI MM (normal) individuals was significantly increased at 3.26 (95% confidence intervals (CI): 1.24-8.57). In 17 cross-sectional and case-control studies, the OR for COPD in PI MS heterozygotes was 1.19 (95%CI: 1.02-1.38). However, PI MS genotype was not associated with COPD risk after correcting for smoking. Furthermore, mean forced expiratory volume in one second, a measure of airflow obstruction and a defining feature of COPD, did not differ between PI MS and PI MM individuals. There were not enough cases to summarise the risk of COPD in PI SS homozygotes. In conclusion, the results show that the PI SZ genotype is a significant risk factor for chronic obstructive pulmonary disease. The risk of chronic obstructive pulmonary disease due to the PI MS genotype is not substantially elevated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994391     DOI: 10.1183/09031936.05.00135704

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

Review 1.  Pharmacogenomics of chronic obstructive pulmonary disease.

Authors:  Craig P Hersh
Journal:  Expert Rev Respir Med       Date:  2019-04-08       Impact factor: 3.772

2.  SERPINA1 and ELA2 polymorphisms are not associated with COPD or lung cancer.

Authors:  Lindsey Enewold; Leah E Mechanic; Elise D Bowman; Elizabeth A Platz; Anthony J Alberg
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

3.  Alpha-1-antitrypsin deficiency in Serbian adults with lung diseases.

Authors:  Aleksandra Topic; Marija Stankovic; Aleksandra Divac-Rankov; Natasa Petrovic-Stanojevic; Marija Mitic-Milikic; Ljudmila Nagorni-Obradovic; Dragica Radojkovic
Journal:  Genet Test Mol Biomarkers       Date:  2012-09-12

4.  Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?

Authors:  Dawn McGee; Laura Schwarz; Rebecca McClure; Lauren Peterka; Farshid Rouhani; Mark Brantly; Charlie Strange
Journal:  Pulm Med       Date:  2010-06-28

Review 5.  National Emphysema Treatment Trial state of the art: genetics of emphysema.

Authors:  Craig P Hersh; Dawn L DeMeo; Edwin K Silverman
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

6.  Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency.

Authors:  Alessandro N Franciosi; Brian D Hobbs; Oliver J McElvaney; Kevin Molloy; Craig Hersh; Louise Clarke; Cedric Gunaratnam; Edwin K Silverman; Tomás P Carroll; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

7.  Considerations for designing a prototype genetic test for use in translational research.

Authors:  C H Wade; C M McBride; S L R Kardia; L C Brody
Journal:  Public Health Genomics       Date:  2009-09-03       Impact factor: 2.000

8.  SERPINA2 is a novel gene with a divergent function from SERPINA1.

Authors:  Patrícia Isabel Marques; Zélia Ferreira; Manuella Martins; Joana Figueiredo; Diana Isabel Silva; Patrícia Castro; Ramiro Morales-Hojas; Joana Simões-Correia; Susana Seixas
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

Review 9.  Markers of early disease and prognosis in COPD.

Authors:  Morten Dahl; Børge G Nordestgaard
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15

10.  SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort.

Authors:  Gian-Andri Thun; Ilaria Ferrarotti; Medea Imboden; Thierry Rochat; Margaret Gerbase; Florian Kronenberg; Pierre-Olivier Bridevaux; Elisabeth Zemp; Michele Zorzetto; Stefania Ottaviani; Erich W Russi; Maurizio Luisetti; Nicole M Probst-Hensch
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.